Commercialization Readiness from Preclinical to 1st Launch: The First Time CEOs Playbook will equip early-stage biotechnology leaders with the commercialization knowledge they need to strategically position their organizations for financing success and meet critical Commercial and Medical Affairs milestones. The drug development process is complex and multifaceted, and understanding the commercialization considerations at each phase is vital. From preclinical to first product launch, this one-day course will help biotech executives make informed strategic choices for long-term success. Beginning with Phase I, this interactive course will cover the phase-specific commercialization activities and preparation emerging companies need to make for a successful first launch, including Market analysis with competitive landscape assessment, the Commercialization Roadmap development including launch critical success factors, FTEs and dollar spend required for launch, market access pricing and reimbursement, value proposition development, and go-to-market preparation and regulatory considerations. Note that these early commercial flows inform emerging biotech companies' corporate and partnering strategies. Russ Belden, founder and CEO of Bridge, will guide you through this course by sharing real-world examples and valuable insights. Russ is a biotech commercialization leader with over 36 years of senior operational experience in the preclinical to 1st launch space and a popular Biotech Primer instructor. About Biotech Primer:Biotech Primer is a trusted leader in delivering life sciences training that simplifies complex topics for non-scientists. With over 20 years of experience, industry-specific courses are expertly crafted to provide a clear understanding of the science, business, and regulatory frameworks essential for success in Biotechnology, Pharmaceuticals, Molecular Diagnostics, and Medical Devices. All BIO members receive a 15% discount on all…

The "Product & Company Valuation" course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic development decisions in the pharma-biotech world. This introductory course is very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors, which shape the risk profile of the company in question. This course optimally balances interactive lectures with practical group work exercises that are designed to help you practice the fundamental valuation tools & techniques taught throughout the day.Valuation is an inherently subjective task, which is made even more difficult in the life science industry due to its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies, IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the “Product Valuation and Deal Structuring” module where registrants will learn the commonly used rNPV (i.e., risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. Registrants will use an Excel-based tool designed specifically for this module, which can be taken home for future use.Topics covered in the Product & Company Valuation course include:Introduction to valuationAssessing a company prior to valuationCompany valuation and methodsProduct valuation and methodsDeal structuringThis one-day course will be held in person on June 15, 2025, in Boston. Registration opens on January 27, 2025. …